Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) was emerged in 2003, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) got reported in the year 2012. Following, SARS-CoV-2 was observed as pandemic around the globe in the end of 2019. COVID-19 has produced significant rate of morbidity and mortality rate causing severe loss of life. An immediate attention is required to find out active therapeutic methods and appropriate vaccines to control this epidemic condition. This is the crucial time to find out the lead compounds for the inhibition of SARS-CoV-2 by targeting its enzymes. The present review will make it possible to better understand the pathogenesis caused by the virus through their various proteins and finding path for the development of effective new drug targets and vaccines for this newly raised pathogen. In order to achieve these objectives, the current review will focus on the biology of the virus and describe the chemistry of a cellular targeted drug delivery pattern of two novel drug conjugates: HA-2-Deoxy-D-Glucose and HA-Hydroxychloroquine for treatment of COVID-19.
